M&A is a key component of evolving business strategies that will enable companies to better compete in a value-driven market.
Mark Bonifacio recently contributed to an “M&A Roundtable” article for MPO magazine where multiple industry leaders weighed in on the M&A growth, trends and challenges in the MedTech sector. Here’s an excerpt:
“Firepower is amassing from outside the life sciences sector altogether,” EY’s report states. “In an October 2017 EY survey, life sciences executives pegged increased competition from companies outside the industry as the top disruptive force. This effect on the life sciences industry is too big to ignore, especially as several well-capitalized players such as Amazon, Apple, Alphabet, and Tencent openly muse about the future impact they may have on healthcare. Several of these companies are already placing bets alongside traditional life sciences plays, either as strategic investors or joint venture partners. Their investments follow major commitments to health care from the likes of IBM (Watson), Intel, and Samsung, among others.”
To better assess this impending onslaught from non-traditional healthcare entities as well as the breadth and depth of medtech’s M&A firepower this year (with “firepower” defined by EY as a company’s ability to perform an M&A transaction based on its balance sheet strength), Medical Product Outsourcing spoke with more than a half-dozen experts over the last few weeks (including our own Mark Bonifacio).